NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
4/8 — Partial
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROCKLATAN is a fixed-dose combination ophthalmic solution containing netarsudil (a Rho kinase inhibitor) and latanoprost (a prostaglandin F analog) approved in March 2019 for reducing intraocular pressure in glaucoma and ocular hypertension patients. The dual mechanism targets multiple pathways to lower IOP: netarsudil increases conventional and uveoscleral outflow while latanoprost enhances uveoscleral drainage. This combination allows once-daily dosing and improved patient compliance.
$0.146BPart D
Peak7.6 years to LOEProduct is at peak revenue maturity with $146M annual spending across 273K+ claims, indicating stable commercial infrastructure and established brand presence with potential for modest growth or defense.
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Started Jul 2026
50 enrolled
Ocular HypertensionSuspect Glaucoma
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Started Jun 2026
50 enrolled
GlaucomaOcular Hypertension
Rocklatan Retinal Perfusion OCT Study
Started Jan 2026
30 enrolled
Glaucoma
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Started Nov 2025
30 enrolled
Open Angle GlaucomaOcular Hypertension
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Started Sep 2025
489 enrolled
Ocular HypertensionOpen Angle Glaucoma
Worked on ROCKLATAN at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.